Reclast is indicated to treat postmenopausal osteoporosis; to reduce the incidence of new clinical fractures in patients at high risk of fractures (those with recent low–trauma hip fracture); and for the prevention of osteoporosis in postmenopausal women. Reclast is also indicated to increase bone mass in men with osteoporosis; for the treatment of Paget’s disease of bone (men and women); and for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women expected to be on glucocorticoids for at least 12 months.
Zoledronic acid, a bisphosphonate, works primarily on the bone. It is an inhibitor of osteoclast-mediated bone resorption. Intravenous administration of zoledronic acid provides rapid and preferential distribution to areas of high bone turnover. Common adverse events associated with zoledronic acid include flu-like illness and gastrointestinal symptoms.
Mylan’s Zoledronic Acid Injection is available as in 5mg/100mL single-dose vials.
For more information call (800) RX-MYLAN or visit Mylan.com.